Eosinophilic Esophagitis (EoE) is a chronic condition of the esophagus. White blood cells such as eosinophils, mast cells and lymphoid cells enter the tissue of the esophagus, causing inflammation. EoE cases have increased dramatically all over the world in recent years.
Someone experiencing EoE often feels difficulty or pain swallowing, chest pain and heartburn. Food may even get stuck in the esophagus, requiring visits to the emergency.
To prevent this, doctors and dietitians may recommend a diet avoiding foods more likely to cause those issues. Some treatments to manage EoE also exist.
Living and managing EoE can feel overwhelming, leading to anxiety and even depression.
American Partnership for Eosinophilic Disorders (APFED)
A U.S.-based nonprofit founded in 2001, dedicated to improving EoE patient and family lives through education, advocacy, and research support.
Australian Eosinophilic Diseases Association (ausEE)
A volunteer-run national charity in Australia (also serving New Zealand) providing resources, awareness campaigns, and peer support for those affected by eosinophilic disorders.
Canadian Digestive Health Foundation (CDHF)
A leading Canadian charity offering trustworthy educational content and support for individuals managing digestive diseases, including EoE.
EOS Network
A UK-based global nonprofit fostering patient, professional, and research collaboration around EGIDs such as EoE, offering resources and awareness initiatives.
EUREOS – European Society of Eosinophilic Oesophagitis
A European network of healthcare professionals delivering clinical guidelines, continuing education, and updates on EoE research and patient care.
Knee Osteoarthritis (knee OA) is a chronic, degenerative condition in which the cartilage in your knee breaks down from wear and tear over time. OA impacts over half a billion people worldwide and knee OA is the most common joint affected.
Patients experience knee pain, which becomes more frequent and severe over time. The knee may also appear swollen, feel stiff and locks in place. This reduces mobility, the capacity to go about one’s day, increases disability and may lead to higher healthcare costs, burden and mortality.
OA has no cure, but some treatments can help manage symptoms. When disease progression becomes too severe, knee replacement surgery may be an option.
Arthritis Foundation
U.S. nonprofit supporting individuals living with arthritis through community awareness, policy advocacy, and significant investment in research toward better treatments.
Arthritis Society Canada
Canada’s largest arthritis charity, dedicated to combating arthritis through advocacy, research funding, and patient support across the nation.
European Network on Osteoarthritis (NetwOArk)
A European COST Action initiative forming a collaborative platform of patients, clinicians, and researchers focused on structured OA research and forming the European Society for Osteoarthritis (EUSOA) IMI COST
Osteoarthritis Action Alliance
A U.S.-based coalition led by the Arthritis Foundation and CDC, committed to recognizing osteoarthritis as a public health priority by promoting effective interventions and policies.
At this time, Eupraxia’s investigational drugs are only available through participation in clinical trials. We are committed to advancing our therapies through rigorous studies to ensure safe, effective treatment options for patients worldwide.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia’s product candidates has the potential to address therapeutic areas with high unmet medical need and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects.
Companies engaged in drug development routinely receive inquiries from physicians and patients looking to access investigational drugs prior to their receiving regulatory approval. Expanded access programs are typically geared toward patients with serious or immediately life-threatening diseases who have exhausted their other treatment options.
At this time, Eupraxia does not offer an expanded access program. The Company’s investigational drugs are currently only available through participation in a clinical trial. Clinical trials are controlled studies in humans that are designed to determine if a drug is both safe and effective. Management believes that testing drugs in a closely controlled clinical setting is the most expeditious way to obtain the data needed to apply for marketing authorization. Ultimately, applying for and receiving marketing authorization in jurisdictions globally is the quickest and safest way to ensure a drug is widely available and of benefit to the largest group of patients possible. Eupraxia intends to use the mechanisms made available by regulators to expedite completion of its clinical programs and accelerate the review of any resulting data and/or decisions pertaining to marketing authorization.
Physicians and patients that wish to learn more about Eupraxia’s clinical programs should visit the clinicaltrials.gov website.
Eupraxia reserves the right to modify this policy at any point in the future, including as additional safety and efficacy data becomes available.
Eupraxia is a clinical-stage biotechnology company developing targeted therapies that leverage a proprietary extended-release delivery system to provide the right dose of a drug in the right place for the right amount of time.
Eupraxia Pharmaceuticals
201-2067 Cadboro Bay Rd.
Victoria BC, Canada, V8R 5G4